Butterfly Medical

Company Overview

Snapshot

Founded in October 2014 by Yehuda Bachar and Adrian Paz, Butterfly Medical operates with 11–50 employees. The company has raised $30 million across three funding rounds, with New Rhein Healthcare Investors participating in multiple rounds. In May 2026, Butterfly Medical secured an upsized Series C funding round to further advance its minimally invasive BPH treatment.

Business overview

Butterfly Medical is a Health Tech & Life Sciences company developing an implantable device for the non-surgical treatment of benign prostatic hyperplasia (BPH), commonly known as an enlarged prostate. Its core product, the Butterfly implant, is designed to anatomically fit the prostatic urethra, dilating the obstructed area to restore urine flow and improve patient quality of life. The device offers a minimally invasive treatment option, with the delivery procedure taking minutes to complete. The company serves the urology market, targeting patients suffering from BPH symptoms, and operates within the Medical Devices and Medical Treatment & Therapeutics sectors.

Strategic signal

In May 2026, Butterfly Medical successfully secured an upsized Series C funding round, with participation from investors including. This significant capital infusion signals strong investor confidence in the company's proprietary non-surgical solution for BPH and its potential to advance the treatment into broader markets. It suggests a positive trajectory for the company's ongoing clinical development and commercialization efforts.

Company Intelligence Q&A

What was the most recent funding event for Butterfly Medical?

In May 2026, Butterfly Medical secured an upsized Series C funding round. Investors in this round included European Innovation Council and New Rhein Healthcare Investors.

What is the status of Butterfly Medical's pivotal clinical trial?

In January 2026, Butterfly Medical announced the successful completion of its 244-patient international pivotal clinical study for the Butterfly Prostatic Retraction Device, which is a significant step towards a planned FDA Pre-Market Approval (PMA) application.

When did Butterfly Medical present new data on its BPH device?

In April 2025, Butterfly Medical presented new research highlighting the effectiveness of its minimally invasive device for benign prostatic hyperplasia (BPH) treatment at the American Urological Association's Annual Conference.

Has Butterfly Medical made any recent leadership appointments?

In April 2025, Butterfly Medical appointed Dr. James Ulchaker as its Chief Medical Officer to advance the novel treatment for benign prostatic hyperplasia, supporting efforts toward FDA approval and U.S. commercialization.

Which accelerator programs has Butterfly Medical participated in?

Butterfly Medical graduated from the MedTech Innovator accelerator program in June 2024 and the EIC Accelerator program in March 2023. The company also graduated from MassChallenge Israel in January 2019.